Recap: Relmada Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Relmada Therapeutics (NASDAQ:RLMD) reported Q4 earnings with an EPS of $-0.84, missing estimates by -1.0% and showing no revenue change from the previous year. Last quarter, the company beat EPS estimates which led to a 0.0% change in share price the following day.
March 19, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Relmada Therapeutics reported a slight miss in Q4 earnings with an EPS of $-0.84, missing estimates by -1.0%, and no revenue change from the previous year.
Missing earnings estimates, even by a small margin, can negatively impact investor sentiment and stock price in the short term. The lack of revenue growth could also be a concern for investors looking for signs of growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100